Results 91 to 100 of about 21,488 (194)

The Twelve-Month Outcome of Biolimus Eluting Stent with Biodegradable Polymer Compared With an Everolimus Eluting Stent with Durable Polymer

Journal of Cardiovascular and Thoracic Research, 2011
Introduction: Drug-eluting stents (DES) have significantly decreased the need for repeat coronary revascularization but concerns remain regarding the safety of first and second generation DES.
Ahmad Separham, Bahram Sohrabi, Naser Aslanabadi, Samad Ghaffari   +3 more
doaj   +1 more source

Identification of endothelial protein C receptor as a novel druggable agonistic target for reendothelialization promotion and thrombosis prevention of eluting stent

Bioactive Materials
The commercially available drug-eluting stent with limus (rapamycin, everolimus, etc.) or paclitaxel inhibits smooth muscle cell (SMC), reducing the in-stent restenosis, whereas damages endothelial cell (EC) and delays stent reendothelialization ...
Jing Chen, Changyi Zhou, Weilun Fang, Jiasheng Yin, Jian Shi, Junbo Ge, Li Shen, Shi-Ming Liu, Shao-Jun Liu   +8 more
doaj   +1 more source

Drug-Eluting Balloon: An Overview of Clinical Evidences on Safety and Effectiveness

Journal of Pharmacoeconomics and Pharmaceutical Management, 2015
Background: Recent advances in the intravascular diseases have led to the entrance of drug-eluting balloon (DEB) technology. The DEB is a relatively new and easier way to treat vascular stenosis.
Khosro Keshavarz, Amir Hashemi-Meshkini, Pardis Zaboli, Jamal Khedmati, Abbas Kebriaeezadeh   +4 more
doaj  

Comparative outcomes of drug eluting stents and drug eluting balloons in treating in-stent restenosis

Archives of Medical Science – Atherosclerotic Diseases
IntroductionSeveral treatment modalities have been proposed and used for bare-metal in-stent restenosis (ISR). We compared the efficacy of drug-eluting balloons (DEB) versus drug-eluting stents (DES) in the treatment of ISR in terms of binary restenosis, target lesion revascularization (TLR) and late lumen loss (LLL) by coronary angiography at 6 months.
Neeraj Mahajan, Gautam Singal, Munish Sharma   +2 more
openaire   +2 more sources

ISEV2026 Abstract Book

Journal of Extracellular Vesicles, Volume 15, Issue S1, June 2026.
wiley   +1 more source

Drug-eluting stents : Insights into safety and indications

Annals of Saudi Medicine, 2008
Currently, more than 4 million patients receive drug-eluting stents worldwide. Despite recent studies and editorials that have stirred controversy and generated tremendous publicity in the lay press related to the safety of drug-eluting stents for the ...
Hassan Walid
doaj  

Biodegradable polymer Biolimus-eluting stent (Nobori®) for the treatment of coronary artery lesions: review of concept and clinical results

Medical Devices: Evidence and Research, 2014
Guillaume Schurtz,1,2 Cédric Delhaye,1 Christopher Hurt,1,2 Henri Thieuleux,1,2 Gilles Lemesle1–3 1Centre Hémodynamique et Unité des Soins Intensifs de Cardiologie, Hôpital Cardiologique, Centre Hospitalier Ré ...
Schurtz G, Delhaye C, Hurt C, Thieuleux H, Lemesle G   +4 more
doaj  

Very Late Fracture of a First-Generation Drug-Eluting Stent. [PDF]

JACC Case Rep
Tsakirian F, Afendoulis D, Tsalamandris S, Synetos A, Tsioufis K, Toutouzas K.   +5 more
europepmc   +1 more source

Sex Differences in Prognostic Implications of CYP2C19 Genotype After Drug-Eluting Stent Implantation. [PDF]

J Am Heart Assoc
Kim SJ, Her AY, Joo HJ, Chang K, Kim BK, Song YB, Ahn SG, Suh JW, Lee SY, Cho JR, Kim HS, Jeong YH, Kim MH, Lim DS, Shin ES.   +14 more
europepmc   +1 more source

Intentional retrieval of a protruding ostial left main drug-eluting stent using a snare: a bail-out case report. [PDF]

Eur Heart J Case Rep
Sarsari M, Bachri H, Kerrouani O, Zarzur J, Cherti M.   +4 more
europepmc   +1 more source